<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524887</url>
  </required_header>
  <id_info>
    <org_study_id>161003</org_study_id>
    <secondary_id>2011-000914-21</secondary_id>
    <nct_id>NCT01524887</nct_id>
  </id_info>
  <brief_title>Phase 3 IGIV, 10% in Alzheimer´s Disease</brief_title>
  <official_title>A Phase 3 Randomized, Double-blind, Placebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide evidence of efficacy and safety to support the
      development of IGIV, 10% as a treatment option for patients with mild to moderate Alzheimer´s
      Disease.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated because the first Phase 3 did not demonstrate efficacy on the
    co-primary endpoints. The known safety profile remained unchanged.
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)</measure>
    <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
    <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory</measure>
    <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
    <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADCS-Clinical Global Impression of Change (CGIC) at 18 Months</measure>
    <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
    <description>The ADCS-CGIC is a validated categorical measure of change in a participant's global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
    <description>The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement</measure>
    <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)</measure>
    <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
    <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)</measure>
    <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
    <description>The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)</measure>
    <time_frame>Throughout the study period: 18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Any AEs and/or SAEs</measure>
    <time_frame>Throughout the study period: 18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions Temporally Associated With AEs and/or SAEs</measure>
    <time_frame>During or within 72 hours of completion of an infusion</time_frame>
    <description>A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion</measure>
    <time_frame>During or within 7 days of completion of an infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions Causally Associated With AEs and/or SAEs</measure>
    <time_frame>Throughout the study period: 18 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE</measure>
    <time_frame>Throughout infusions, approximately 2-5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Alzheimer´s Disease</condition>
  <arm_group>
    <arm_group_label>IGIV, 10% at high dose (0.4 g/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IGIV, 10% at low dose (0.2 g/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune Globulin Intravenous (Human), 10% Solution</intervention_name>
    <description>Intravenous infusion every 2 weeks over 18 months</description>
    <arm_group_label>IGIV, 10% at high dose (0.4 g/kg)</arm_group_label>
    <arm_group_label>IGIV, 10% at low dose (0.2 g/kg)</arm_group_label>
    <other_name>IGIV, 10%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human albumin 0.25%</intervention_name>
    <description>Intravenous infusion every 2 weeks over 18 months</description>
    <arm_group_label>Placebo control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females of age 50 to 89 years inclusive at the time of screening

          -  Written informed consent obtained from either the subject or the subject's legally
             authorized representative prior to any study-related procedures

          -  Written informed consent obtained from an able and competent caregiver who is willing
             to comply with the requirements of the protocol pertaining to him/her, including
             facilitating the subject's participation in the study

          -  Diagnosis of Probable Alzheimer´s Disease (AD) according to NINCDS-ADRDA* 1984
             criteria (* National Institute of Neurological and Communicative Disorders and Stroke
             - Alzheimer's Disease and Related Disorders Association)

          -  Dementia of mild to moderate severity (Mini-Mental State Examination [MMSE] 16-26
             inclusive at the time of screening)

          -  Neuroimaging (computed tomography [CT] or MRI) performed after symptom onset
             consistent with AD diagnosis

          -  Willingness to comply with the requirements of the protocol and ability to comply with
             testing and infusion regimen, including adequate corrected visual acuity and hearing
             ability

          -  For at least 12 weeks prior to screening, on stable doses of AD medication(s) approved
             by local regulatory authorities. Subjects must not be on two acetylcholinesterase
             inhibitors concurrently.

          -  Venous access for repeated infusion and phlebotomy

          -  If receiving psychoactive medications (eg, antidepressants other than monoamine
             oxidase inhibitors [MAOIs] and most tricyclics, antipsychotics, anxiolytics,
             anticonvulsants, mood stabilizers, etc.), must be on stable doses for at least 6 weeks
             prior to screening

          -  For women of childbearing potential, the subject must have a negative pregnancy test
             at screening and must agree to employ adequate contraceptive measures (eg, birth
             control pills/patches, intrauterine device, or diaphragm or condom [for male partner]
             with spermicidal jelly or foam) throughout the course of the study

          -  For subjects with a coronary artery stent, the subject must receive documented medical
             clearance from an interventional cardiologist stating that the subject is not at
             increased risk for stent occlusion with immunoglobulin treatment

          -  For subjects with an endovascular stent, the subject must receive documented medical
             clearance from a vascular surgeon stating that the subject is not at increased risk
             for thromboembolic events with immunoglobulin treatment

        Main Exclusion Criteria:

          -  Possible AD by NINCDS-ADRDA criteria or non-Alzheimer dementia (eg, vascular dementia,
             dementia with Lewy bodies, frontotemporal dementia, or dementia arising from other
             diseases or conditions such as Parkinson's disease, vitamin B12 deficiency, thyroid
             abnormalities)

          -  Current residence in a skilled nursing facility

          -  Contraindication to undergoing MRI (eg, pacemaker [with the exception of an
             MRI-compatible pacemaker], severe claustrophobia, ferromagnetic implants such as a
             metal plate)

          -  Clinically significant congestive heart failure (eg, New York Heart Association [NYHA]
             Class III/IV symptoms or untreated Class II)

          -  Current atrial fibrillation of unstable angina (angina at rest) or history of
             myocardial infarction within the 12 months prior to screening

          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 160 mm Hg and/or
             diastolic &gt; 100 mm Hg confirmed upon repeated measures

          -  History of thrombosis and/or thromboembolic disease (central or peripheral) within the
             12 months prior to screening

          -  Known history of procoagulant abnormalities (eg, factor V Leiden, antiphospholipid
             syndrome, protein S/protein C deficiency, AT III deficiency)

          -  History of intracerebral hemorrhage within the 5 years prior to screening

          -  Evidence on MRI of: greater than 4 microhemorrhages (regardless of their anatomical
             location or diagnostic characterization as &quot;possible&quot; or &quot;definite&quot;), a single area of
             superficial siderosis, vasogenic edema, a macrohemorrhage, major stroke, prominent
             white matter disease with a rating score of 3 on the age-related white matter changes
             (ARWMC) scale from the European Task Force on ARWMC, or multiple lacunae (defined as
             more than 2 lacunae that are greater than 0.5 mm in size)

          -  Head trauma with loss of consciousness, contusion, or open head injury within the 12
             months prior to screening

          -  Uncontrolled seizure disorder as defined by two or more breakthrough seizures per year
             despite adequate antiepileptic drug (AED) treatment

          -  Modified Hachinski score &gt; 4 at time of screening

          -  Subjects with active malignancy or history of malignancy within 5 years prior to
             screening with the exception of the following: adequately treated basal cell or
             squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and stable
             prostate cancer not requiring treatment

          -  Active autoimmune or neuro-immunologic disorder

          -  Uncontrolled major depression, psychosis, or other major psychiatric disorder(s)

          -  Poorly controlled diabetes, defined as glycosylated (or glycated) hemoglobin (HbA1c) ≥
             6.5% at screening

          -  Creatinine clearance &lt; 50% of normal adjusted for age and gender, as calculated
             according to the Cockcroft-Gault formula, at the time of screening

          -  Known history of untreated vitamin B12 deficiency within 6 months prior to screening,
             or clinically significant abnormally low vitamin B12 at the time of screening

          -  Abnormal clinical chemistry panel or hematology panel meeting any one of the following
             criteria:

          -  Serum alanine aminotransferase (ALT) &gt; 2.5 x upper limit of normal (ULN)

          -  Clinically significant anemia that precludes repeated blood sampling or hemoglobin
             (Hgb) &lt; 10.0 g/dL

          -  Absolute neutrophil count (ANC) &lt; 1000 cells/µL

          -  Known coagulopathy or platelet counts &lt; 100,000 cells/µL

          -  Total serum protein &gt; 9 g/dL

          -  Known history of or positive serology at screening for one or more of the following:
             hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human
             immunodeficiency virus (HIV) type 1/2 antibody

          -  Immunoglobulin A (IgA) deficiency (&lt; 8 mg/dL)

          -  Known history of hypersensitivity following infusions of human blood or blood
             components (e.g. human immunoglobulins or human albumin)

          -  Currently receiving or has received: anti-CD20 therapy within 12 months prior to
             screening, or other immunomodulatory therapies (e.g. anti-TNF, anti-IL-1, interferon)
             within 12 weeks prior to screening. The following exceptions are allowed: non-systemic
             corticosteroids (eg, topical, opthalmic or inhaled glucocorticoids) and low-dose
             systemic corticosteroids (prednisone &lt; 10 mg/day or its equivalent)

          -  Currently receiving or has received intravenous or subcutaneous immunoglobulin
             treatment within the 2 years prior to screening, or has received immunoglobulin in
             Baxter Protocol 160701

          -  Currently receiving or has received at any time active immunization aimed at
             modulating AD progression

          -  Currently receiving or has received within 12 months prior to screening any
             investigational device, drug or biologic (eg passive immunotherapies with monoclonal
             or polyclonal antibodies) aimed at modulating AD progression

          -  Subject has been exposed to an investigational product (IP) or investigational device
             within 12 weeks prior to screening or is scheduled to participate in another clinical
             study involving an IP or investigational device during the course of this study

          -  Subject is a family member or employee of the investigator

          -  The subject is nursing or intends to begin nursing during the course of the study

          -  Any disorder or disease, or clinically significant abnormality on laboratory or other
             clinical test(s) (eg, blood tests, urine tests, electrocardiogram, chest x-ray), that
             in medical judgment may impede the subject's participation in the study, pose
             increased risk to the subject, or confound the results of the study

          -  Currently receiving anti-coagulant agent and/or anti-platelet agent other than
             acetylsalicylic acid (a.k.a. aspirin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Tobias, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chester</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eatontown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Latham</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akashi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Azumino</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scinawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cruces-Barakaldo</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uckfield</city>
        <state>East Sussex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brentford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2012</study_first_submitted>
  <study_first_submitted_qc>January 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2012</study_first_posted>
  <results_first_submitted>February 3, 2015</results_first_submitted>
  <results_first_submitted_qc>March 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 31, 2015</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted at 58 clinical sites worldwide.</recruitment_details>
      <pre_assignment_details>Of 508 enrolled subjects, 303 met entry criteria. 42 subjects discontinued before randomization due to study termination. Of 261 randomized subjects, 10 subjects discontinued before receiving treatment (7 study termination, 2 withdrawal by subject, 1 withdrawal by caregiver). Number of subjects who received treatment (IVIG,10% or placebo) = 251.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
          <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
        <group group_id="P2">
          <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
          <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
        <group group_id="P3">
          <title>Placebo Control</title>
          <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">No subject completed the study as Baxter Healthcare terminated the study early.</participants>
                <participants group_id="P2" count="0">No subject completed the study as Baxter Healthcare terminated the study early.</participants>
                <participants group_id="P3" count="0">No subject completed the study as Baxter Healthcare terminated the study early.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study termination</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="79"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Caregiver</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Use of prohibited medication</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population comprises treated subjects (=safety analysis set).</population>
      <group_list>
        <group group_id="B1">
          <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
          <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
        <group group_id="B2">
          <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
          <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
        <group group_id="B3">
          <title>Placebo Control</title>
          <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="83"/>
            <count group_id="B4" value="251"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.0" spread="8.36"/>
                    <measurement group_id="B2" value="69.9" spread="8.59"/>
                    <measurement group_id="B3" value="70.6" spread="9.98"/>
                    <measurement group_id="B4" value="70.8" spread="9.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="238"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)</title>
        <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer’s Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
        <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
        <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)</title>
          <description>The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer’s Disease Cooperative Study (ADCS) at each site.
Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.</description>
          <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="6.44"/>
                    <measurement group_id="O2" value="4.4" spread="8.56"/>
                    <measurement group_id="O3" value="3.1" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.243</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.370</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>3.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory</title>
        <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
        <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
        <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 18 in Alzheimer´s Disease Cooperative Study (ADCS)-Activities of Daily Living (ADL) Inventory</title>
          <description>The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner.
Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.</description>
          <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" spread="7.36"/>
                    <measurement group_id="O2" value="-5.0" spread="11.64"/>
                    <measurement group_id="O3" value="-3.8" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-7.4</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.586</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADCS-Clinical Global Impression of Change (CGIC) at 18 Months</title>
        <description>The ADCS-CGIC is a validated categorical measure of change in a participant’s global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).</description>
        <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
        <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>ADCS-Clinical Global Impression of Change (CGIC) at 18 Months</title>
          <description>The ADCS-CGIC is a validated categorical measure of change in a participant’s global clinical status between baseline and follow-up visits, based on interview of the participant and the caregiver by a skilled and experienced clinician who was blinded to treatment assignment. The ADCS-CGIC score is based on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening).</description>
          <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="3.7" upper_limit="4.8"/>
                    <measurement group_id="O2" value="4.4" lower_limit="4.0" upper_limit="4.9"/>
                    <measurement group_id="O3" value="4.5" lower_limit="4.1" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.501</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.783</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)</title>
        <description>The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.</description>
        <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
        <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 18 in Neuropsychiatric Inventory (NPI)</title>
          <description>The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 10 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.</description>
          <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="5.76"/>
                    <measurement group_id="O2" value="3.8" spread="12.44"/>
                    <measurement group_id="O3" value="0.6" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.571</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement</title>
        <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
        <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 18 in Volumetric Magnetic Resonance Imaging (MRI) Parameters: Rate of Whole Brain Atrophy and Ventricular Enlargement</title>
          <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
          <units>mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00065" spread="0.00059"/>
                    <measurement group_id="O2" value="0.00057" spread="0.00070"/>
                    <measurement group_id="O3" value="0.00067" spread="0.00163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.593</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.00026</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.00126</ci_lower_limit>
            <ci_upper_limit>0.00073</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.940</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in least square means</param_type>
            <param_value>0.00003</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.00080</ci_lower_limit>
            <ci_upper_limit>0.00086</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)</title>
        <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.</description>
        <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
        <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 18 in Logsdon Quality of Life in Alzheimer´s Disease (QOL-AD)</title>
          <description>The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant´s quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52, with lower scores associated with a lower quality of life.</description>
          <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="4.43"/>
                    <measurement group_id="O2" value="0.4" spread="3.68"/>
                    <measurement group_id="O3" value="0.1" spread="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.633</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.981</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Difference in least square means</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)</title>
        <description>The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.</description>
        <time_frame>Baseline to 9 Months (actual time frame)</time_frame>
        <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Month 18 in Impact of Alzheimer´s Disease on Caregiver Questionnaire (IADCQ)</title>
          <description>The IADCQ is a 12-item validated questionnaire that has been developed to measure the emotional, physical, and social impact of care giving on AD caregivers. Higher scores on the IADCQ are associated with a higher impact. IADCQ total score range: 0 (no impact) - 48 (greatest impact). Each item can be scored either 0 (Not at all), 1 (A little), 2 (Somewhat), 3 (A lot), or 4 (Extremely). As this is a 12-item scale, the minimum possible score is 0 and the maximum possible score is 4x12 = 48.</description>
          <population>Because this study was terminated early, 9-month analyses were conducted in the subset of participants that completed at least 9 months of treatment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="4.13"/>
                    <measurement group_id="O2" value="1.9" spread="6.66"/>
                    <measurement group_id="O3" value="1.4" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)</title>
        <time_frame>Throughout the study period: 18 Months</time_frame>
        <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Study Product-related Adverse Events (AEs) and/or Serious Adverse Events (SAEs)</title>
          <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with product-related AEs (incl SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with product-related non-serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with product-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Any AEs and/or SAEs</title>
        <time_frame>Throughout the study period: 18 Months</time_frame>
        <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Any AEs and/or SAEs</title>
          <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs (incl SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with non-serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with serious AEs (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions Temporally Associated With AEs and/or SAEs</title>
        <description>A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.</description>
        <time_frame>During or within 72 hours of completion of an infusion</time_frame>
        <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Temporally Associated With AEs and/or SAEs</title>
          <description>A temporal association was defined as an AE and/or SAE occurring during or within 72 hours of completion of an infusion, regardless of causality.</description>
          <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
          <units>infusions</units>
          <param>Number</param>
          <units_analyzed>Total number of infusions administered</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of infusions administered</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="817"/>
                <count group_id="O2" value="935"/>
                <count group_id="O3" value="1023"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion</title>
        <time_frame>During or within 7 days of completion of an infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Associated With AEs and/or SAEs Occurring During or Within 7 Days of Completion of an Infusion</title>
          <units>infusions</units>
          <param>Number</param>
          <units_analyzed>Total number of infusions administered</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of infusions administered</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="817"/>
                <count group_id="O2" value="935"/>
                <count group_id="O3" value="1023"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions Causally Associated With AEs and/or SAEs</title>
        <time_frame>Throughout the study period: 18 Months</time_frame>
        <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Causally Associated With AEs and/or SAEs</title>
          <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
          <units>infusions</units>
          <param>Number</param>
          <units_analyzed>Total number of infusions administered</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of infusions administered</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="817"/>
                <count group_id="O2" value="935"/>
                <count group_id="O3" value="1023"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE</title>
        <time_frame>Throughout infusions, approximately 2-5 hours</time_frame>
        <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
        <group_list>
          <group group_id="O1">
            <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O2">
            <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
            <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
          <group group_id="O3">
            <title>Placebo Control</title>
            <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Discontinued, Slowed, or Interrupted Due to an AE</title>
          <population>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product.</population>
          <units>infusions</units>
          <param>Number</param>
          <units_analyzed>Total number of infusions administered</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Total number of infusions administered</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="817"/>
                <count group_id="O2" value="935"/>
                <count group_id="O3" value="1023"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period. The study was terminated early and no subject completed 18 months of treatment as planned per protocol. The duration of exposure to the investigational product varied for each subject.</time_frame>
      <desc>The safety analysis population includes the 251 subjects who received at least 1 infusion of investigational product (High Dose group: 83, Low Dose group: 85, Placebo group: 83).</desc>
      <group_list>
        <group group_id="E1">
          <title>IGIV, 10% at High Dose (0.4 g/kg)</title>
          <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
        <group group_id="E2">
          <title>IGIV, 10% at Low Dose (0.2 g/kg)</title>
          <description>Immune Globulin Intravenous (Human), 10% Solution: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
        <group group_id="E3">
          <title>Placebo Control</title>
          <description>Human albumin 0.25%: Intravenous infusion every 2 weeks over 18 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Human Ehrlichiosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Spinal Cord Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Infusion Site Extravasation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="83"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" events="19" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For this study, PIs are restricted from independently publishing results before completion of a single multicenter publication or one year after study completion, whichever occurs first. Baxter requires a review of results communications (e.g., for confidential information) ≥90 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (eg, for intellectual property protection).</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary and secondary outcome measures were originally planned to be assessed at 18 months. However, as the study was terminated early, an analysis was completed at 9 months instead, in a subset of subjects who had received 9 months of treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kathy Tobias, MD, Global Medical Dir, Biotherapeutics, Neurology</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>kathy_tobias@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

